These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

476 related articles for article (PubMed ID: 17144780)

  • 1. Glucocorticoids in multiple sclerosis and experimental autoimmune encephalomyelitis.
    Reichardt HM; Gold R; Lühder F
    Expert Rev Neurother; 2006 Nov; 6(11):1657-70. PubMed ID: 17144780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucocorticoids in the control of neuroinflammation.
    Tischner D; Reichardt HM
    Mol Cell Endocrinol; 2007 Sep; 275(1-2):62-70. PubMed ID: 17555867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug targeting by long-circulating liposomal glucocorticosteroids increases therapeutic efficacy in a model of multiple sclerosis.
    Schmidt J; Metselaar JM; Wauben MH; Toyka KV; Storm G; Gold R
    Brain; 2003 Aug; 126(Pt 8):1895-904. PubMed ID: 12805101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brain microglia and blood-derived macrophages: molecular profiles and functional roles in multiple sclerosis and animal models of autoimmune demyelinating disease.
    Raivich G; Banati R
    Brain Res Brain Res Rev; 2004 Nov; 46(3):261-81. PubMed ID: 15571769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Central nervous system penetration for small molecule therapeutic agents does not increase in multiple sclerosis- and Alzheimer's disease-related animal models despite reported blood-brain barrier disruption.
    Cheng Z; Zhang J; Liu H; Li Y; Zhao Y; Yang E
    Drug Metab Dispos; 2010 Aug; 38(8):1355-61. PubMed ID: 20427691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of neurotrophic factors in the pathology and treatment of multiple sclerosis.
    Mirowska-Guzel D
    Immunopharmacol Immunotoxicol; 2009; 31(1):32-8. PubMed ID: 18792835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The translation of drug efficacy from in vivo models to human disease with special reference to experimental autoimmune encephalomyelitis and multiple sclerosis.
    Bolton C
    Inflammopharmacology; 2007 Oct; 15(5):183-7. PubMed ID: 17943249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The potential role of T cell migration and chemotaxis as targets of glucocorticoids in multiple sclerosis and experimental autoimmune encephalomyelitis.
    Fischer HJ; Schweingruber N; Lühder F; Reichardt HM
    Mol Cell Endocrinol; 2013 Nov; 380(1-2):99-107. PubMed ID: 23578583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: consequences for mode of action in multiple sclerosis.
    Foster CA; Howard LM; Schweitzer A; Persohn E; Hiestand PC; Balatoni B; Reuschel R; Beerli C; Schwartz M; Billich A
    J Pharmacol Exp Ther; 2007 Nov; 323(2):469-75. PubMed ID: 17682127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunoglobulins treatment in multiple sclerosis and experimental autoimmune encephalomyelitis.
    Achiron A; Miron S
    Mult Scler; 2000 Oct; 6 Suppl 2():S6-8; discussion S33. PubMed ID: 11188777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histamine and histamine receptors in pathogenesis and treatment of multiple sclerosis.
    Jadidi-Niaragh F; Mirshafiey A
    Neuropharmacology; 2010 Sep; 59(3):180-9. PubMed ID: 20493888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antioxidant therapy in multiple sclerosis.
    Mirshafiey A; Mohsenzadegan M
    Immunopharmacol Immunotoxicol; 2009; 31(1):13-29. PubMed ID: 18763202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of glucocorticoids in the control of neuroinflammation.
    Schweingruber N; Reichardt SD; Lühder F; Reichardt HM
    J Neuroendocrinol; 2012 Jan; 24(1):174-82. PubMed ID: 21615563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The expression and function of chemokines involved in CNS inflammation.
    Ubogu EE; Cossoy MB; Ransohoff RM
    Trends Pharmacol Sci; 2006 Jan; 27(1):48-55. PubMed ID: 16310865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vitamin D as an immune modulator in multiple sclerosis, a review.
    Smolders J; Damoiseaux J; Menheere P; Hupperts R
    J Neuroimmunol; 2008 Feb; 194(1-2):7-17. PubMed ID: 18177949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Experimental allergic encephalomyelitis: a misleading model of multiple sclerosis.
    Sriram S; Steiner I
    Ann Neurol; 2005 Dec; 58(6):939-45. PubMed ID: 16315280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Steroid protection in the experimental autoimmune encephalomyelitis model of multiple sclerosis.
    Garay L; Gonzalez Deniselle MC; Gierman L; Meyer M; Lima A; Roig P; De Nicola AF
    Neuroimmunomodulation; 2008; 15(1):76-83. PubMed ID: 18667803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical, pathological, and immunologic aspects of the multiple sclerosis model in common marmosets (Callithrix jacchus).
    't Hart BA; Massacesi L
    J Neuropathol Exp Neurol; 2009 Apr; 68(4):341-55. PubMed ID: 19337065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Traditional concepts and future avenues of glucocorticoid action in experimental autoimmune encephalomyelitis and multiple sclerosis therapy.
    Lühder F; Reichardt HM
    Crit Rev Immunol; 2009; 29(3):255-73. PubMed ID: 19538138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stress and hypothalamic-pituitary-adrenal axis function in experimental autoimmune encephalomyelitis and multiple sclerosis - a review.
    Heesen C; Gold SM; Huitinga I; Reul JM
    Psychoneuroendocrinology; 2007 Jul; 32(6):604-18. PubMed ID: 17602841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.